Drug · CHEMBL1017

TELMISARTAN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. TELMISARTAN. Drugs and targets, record CHEMBL1017. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1017

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: TELMISARTAN; ChEMBL
ChEMBL ID: CHEMBL1017; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Kinzalmono (previously telmisartan boehringer ingelheim pharma kg), Micardis, Pritor, Semintra, Telmisartan actavis, Telmisartan component of kinzalkomb, Telmisartan component of micardis hct, Telmisartan component of micardisplus, Telmisartan component of onduarp, Telmisartan component of pritorplus, Telmisartan component of tolucombi, Telmisartan component of twynsta, Telmisartan teva, Telmisartan teva pharma, Tolura; ChEMBL
Other names: BIBR 277 SE, BIBR-277, BIBR-277 SE, BIBR-277-SE, Bibr-277se, C09CA07, Kinzalmono, Pritor, Semintra, Telmisartan actavis, Telmisartan teva; ChEMBL
DrugBank: DB00966; DrugBank
InChIKey: RMMXLENWKUUMAY-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 6 of its 54 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
AGTR1	Type-1 angiotensin II receptor	Type-1 angiotensin II receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/185

Source ChEMBL

Diseases54

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hypertensive disorder	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	155	110	https://conductscience.org/library/drugs?q=MONDO_0005044
essential hypertension	Approval	EMA Human Drugs	26	25	https://conductscience.org/library/drugs?q=MONDO_0001134
COVID-19	Phase 3	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0100096
type 2 diabetes mellitus	Phase 3	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0005148
inherited lipid metabolism disorder	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0002525
hyperlipidemia	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0021187
diabetes mellitus	Approval	DailyMed	6	3	https://conductscience.org/library/drugs?q=MONDO_0005015
HIV infectious disease	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005109
chronic kidney disease	Unknown	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005300
diabetic kidney disease	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005016

1 to 10 of 54Source Open Targets

See all 54 diseases

Trials308

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 46 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00153101	Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.	Phase 4	31,546	2009-08-25	telmisartan	Its name	ClinicalTrials.gov
NCT00153062	PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes	Phase 4	20,332	2009-09-02	telmisartan	Its name	ClinicalTrials.gov
NCT00281580	Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension	Phase 3	1,461	2010-04-28	telmisartan	Its name	ClinicalTrials.gov
NCT04518293	Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension	Phase 3	1,385	2025-06-03	telmisartan	Its name	ClinicalTrials.gov
NCT00558428	Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension	Phase 3	1,098	2009-12-15	telmisartan	Its name	ClinicalTrials.gov
NCT00614380	Open Label Study Telmisartan and Amlodipine in Hypertension	Phase 3	976	2010-01-18	telmisartan	Its name	ClinicalTrials.gov
NCT00553267	Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension	Phase 3	947	2009-12-22	telmisartan	Its name	ClinicalTrials.gov
NCT00926289	Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension	Phase 4	894	2011-05-24	telmisartan	Its name	ClinicalTrials.gov
NCT00860262	Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension	Phase 3	858	2011-01-04	telmisartan	Its name	ClinicalTrials.gov
NCT00624052	26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension	Phase 3	838	2010-03-25	telmisartan	Its name	ClinicalTrials.gov

1 to 10 of 308

See all 308 trials

Comparisons in its trials92

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Telmisartan vs Placebo: Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)	880 of 10,146	934 of 10,186	20,332	NCT00153062	Trial comparisons
Telmisartan vs Placebo: Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)	1,367 of 10,146	1,463 of 10,186	20,332	NCT00153062	Trial comparisons
Aspirin + Extended Release Dipyridamole vs Clopidogrel: Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)	1,333 of 10,181	1,333 of 10,151	20,332	NCT00153062	Trial comparisons
Aspirin + Extended Release Dipyridamole vs Clopidogrel: Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)	916 of 10,181	898 of 10,151	20,332	NCT00153062	Trial comparisons
Telmisartan vs Placebo: Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)	125 of 7,306	151 of 7,283	14,589	NCT00153062	Trial comparisons
Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke	384 of 2,954	440 of 2,972	5,926	NCT00153101	Trial comparisons
Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure	465 of 2,954	504 of 2,972	5,926	NCT00153101	Trial comparisons
Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Non-fatal Myocardial Infarction	114 of 2,954	145 of 2,972	5,926	NCT00153101	Trial comparisons
Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Progression to ESRD	11 of 2,954	14 of 2,972	5,926	NCT00153101	Trial comparisons
Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Hospitalization for Congestive Heart Failure	134 of 2,954	129 of 2,972	5,926	NCT00153101	Trial comparisons

1 to 10 of 92

See all 92 comparisons in its trials

Papers from its trials136

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39443527	RESULT	1	PubMed
38380420	RESULT	1	PubMed
22525206	RESULT	1	PubMed
21252701	RESULT	1	PubMed
19683638	RESULT	1	PubMed
19100670	RESULT	1	PubMed
18537808	RESULT	1	PubMed
42130156	DERIVED	1	PubMed
42035974	DERIVED	1	PubMed
42019018	DERIVED	1	PubMed

1 to 10 of 136

See all 136 papers from its trials

Tests in its trials3

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Paired Associate Learning	1	1	ConductCognition
Rapid Visual Information Processing	1	0	ConductCognition
Trail Making Test A	1	0	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL1017

GET https://conductscience.org/api/drugs/v1/CHEMBL1017/diseases?page=2

API reference For AI assistants